Vanda’s social anxiety drug flunks Phase 3 trial in female patients
Phase 3negativeVQW-765Negative
AI Analysis
Summary
Vanda Pharmaceuticals announced that VQW-765, its social anxiety disorder drug, failed to meet the primary endpoint in a Phase 3 trial in female patients, leading the company to put the program on hold.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Missed primary endpoint in Phase 3 trial in female patients
Importance:8/10
Sentiment:
-0.90
phase_3_failuresocial_anxietytrial_discontinuationfemale_patients
Related Companies
Read the original article
Published by Endpoints News on October 15, 2026 11:00 AM